PD29 Using Different Parametric Distributions In Partitioned Survival Analysis: Impact On Incremental Cost-Utility Ratio In A Proportional Hazards Model

Introduction Partitioned survival analysis (PtSA) is a useful modeling technique, especially in oncology, in which different parametric distributions can be used to extrapolate survival data. Many studies lack justification for their chosen distributions, neglecting exploration of uncertainty in extrapolated estimates. We evaluated how different distributions impact the incremental cost-utility ratio (ICUR) for docetaxel, compared with abiraterone plus docetaxel (AA+DTX), for prostate cancer. Methods A three-state PtSA was constructed using overall survival (OS) and progression-free survival (PFS) curves from a docetaxel trial extrapolated over a 20-year horizon with exponential, Weibull, and Gompertz distributions. Log-normal, log-logistic, and generalized gamma were not considered because they are not compatible with the proportional hazards assumption. Curves for AA+DTX were adjusted using hazard ratios (HRs) from indirect comparisons for OS (HR 0.75, 95% confidence interval [CI]: 0.59, 0.95) and PFS (HR 0.50, 95% CI: 0.35, 0.72). Assessment included visual inspection, clinical plausibility, and Akaike and Bayesian information criterion (AIC/BIC) statistics. Utility values, medication costs, and disease monitoring costs were considered based on health state (pre- or post-progression). Results For docetaxel PFS, visual inspection showed no significant differences between the three distributions used for the proportional hazards model, while the exponential model showed the longest tail for OS. When choosing by the lowest AIC/BIC (OS: Weibull; PFS: exponential), cost-effectiveness analysis resulted in an ICUR of BRL79,224 (USD16,139) per quality-adjusted life-year (QALY). The maximum and minimum ICUR was BRL81,559 (USD16,615) (OS: Gompertz; PFS: Weibull) and BRL70,136 (USD14,288) (OS: exponential; PFS: Weibull), respectively, which represented an important variation in the base case scenario (AIC/BIC) ICUR. Conclusions Using the Brazilian cost-effectiveness threshold (BRL120,000 [USD24,446] per QALY gained) and choosing any of the three distributions of the proportional hazards model, AA+DTX would be considered cost effective, which would not change the direction of the recommendation. However, despite the few recommendations in the literature regarding the adoption of parametric models for economic analyses in health, it is important to explore scenarios with different distributions.

Authors

Publication Details

Journal
International Journal of Technology Assessment in Health Care
Published
2024-12-01
DOI
https://doi.org/10.1017/s0266462324002927
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PD29 Using Different Parametric Distributions In Partitioned Survival Analysis: Impact On Incremental Cost-Utility Ratio In A Proportional Hazards Model

Layssa Oliveira, Haliton Alves de Oliveira, Rosa Camila Lucchetta, Ludmila Gargano
International Journal of Technology Assessment in Health Care
Health Systems, Economic Evaluations, Quality of Life
article

PD29 Using Different Parametric Distributions In Partitioned Survival Analysis: Impact On Incremental Cost-Utility Ratio In A Proportional Hazards Model

Layssa Oliveira, Haliton Alves de Oliveira, Rosa Camila Lucchetta, Ludmila Gargano
article en

Abstract

Introduction Partitioned survival analysis (PtSA) is a useful modeling technique, especially in oncology, in which different parametric distributions can be used to extrapolate survival data. Many studies lack justification for their chosen distributions, neglecting exploration of uncertainty in extrapolated estimates. We evaluated how different distributions impact the incremental cost-utility ratio (ICUR) for docetaxel, compared with abiraterone plus docetaxel (AA+DTX), for prostate cancer. Methods A three-state PtSA was constructed using overall survival (OS) and progression-free survival (PFS) curves from a docetaxel trial extrapolated over a 20-year horizon with exponential, Weibull, and Gompertz distributions. Log-normal, log-logistic, and generalized gamma were not considered because they are not compatible with the proportional hazards assumption. Curves for AA+DTX were adjusted using hazard ratios (HRs) from indirect comparisons for OS (HR 0.75, 95% confidence interval [CI]: 0.59, 0.95) and PFS (HR 0.50, 95% CI: 0.35, 0.72). Assessment included visual inspection, clinical plausibility, and Akaike and Bayesian information criterion (AIC/BIC) statistics. Utility values, medication costs, and disease monitoring costs were considered based on health state (pre- or post-progression). Results For docetaxel PFS, visual inspection showed no significant differences between the three distributions used for the proportional hazards model, while the exponential model showed the longest tail for OS. When choosing by the lowest AIC/BIC (OS: Weibull; PFS: exponential), cost-effectiveness analysis resulted in an ICUR of BRL79,224 (USD16,139) per quality-adjusted life-year (QALY). The maximum and minimum ICUR was BRL81,559 (USD16,615) (OS: Gompertz; PFS: Weibull) and BRL70,136 (USD14,288) (OS: exponential; PFS: Weibull), respectively, which represented an important variation in the base case scenario (AIC/BIC) ICUR. Conclusions Using the Brazilian cost-effectiveness threshold (BRL120,000 [USD24,446] per QALY gained) and choosing any of the three distributions of the proportional hazards model, AA+DTX would be considered cost effective, which would not change the direction of the recommendation. However, despite the few recommendations in the literature regarding the adoption of parametric models for economic analyses in health, it is important to explore scenarios with different distributions.

International Journal of Technology Assessment in Health CareVol. 40(S1)
Openalex Percentile: Top 69%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.